摘要
MAIN TEXT Despite improvements in the surveillance,diagnosis,and multimodal therapies for colorectal cancer(CRC),its mortality is persistently high worldwide[1-3].Continuing efforts for controlling CRC using similar strategies seems not sufficient given the persistent threats of CRC on human health.Prevention,in the form of chemoprevention,may provide another cost-effective way to enhance the outcomes of individuals at risk of developing CRC.In this regard,aspirin is emerging as a promising agent in the chemoprevention of CRC,especially for those at risk of cardiovascular diseases.However,the overall efficacy(∼30%)reported from multiple randomized controlled trials is still limited[4-6].The reasons for the limited efficacies of aspirin are elusive.Genetic and epigenetic factors are thought to be critical in relation to drug responses[7,8].
基金
This work was supported in part by the Project 5010 of Sun Yat-sen University(2018004)and a science and technology planning grant from Guangdong province to Shirong Cai.
